MANENYSEPharmaceutical PreparationsFiscal year ends December 31
Veradermics, Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$122.28+13.46 (+12.37%)
Close on Oct 19, 2026
- Market cap
- $4.94B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$83.80 (+217.8%)since Feb 6, 2026
Weekly closes, adjusted for splits, on a log scale. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $4.94B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 6.08
- Dividend yield
- –
- Free cash flow yield
- -1.45%
Fundamentals
- Net income
- -$70.00M
- EPS, diluted
- -$111.91
- Free cash flow
- -$71.63M
- Book value per share
- $20.12
- Diluted shares
- 40M
Three years at a glance
Fiscal years 2023 to 2025, USD
Operating income
-$72.35M
Net income
-$70.00M
EPS, diluted
-$111.91
Free cash flow
-$71.63M
Reported period